Company profile for ValenzaBio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in the heart of the capital biotech community, we strive to work collaboratively with all...
ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in the heart of the capital biotech community, we strive to work collaboratively with all stakeholders while keeping our research and development efforts focused on the needs of patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
6701 Democracy Blvd Suite 300 Bethesda, Maryland 20817
Telephone
Telephone
212 945 8929
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/article/releases/acelyrin-inc-furthers-leadership-position-in-immunology-with-transformative-acquisition-of-valenzabio/?s=79

BIOSPACE
05 Jan 2023

https://www.contractpharma.com/contents/view_breaking-news/2022-06-14/probiogen-valenzabio-enter-second-service-agreement/?widget=listSection

CONTRACTPHARMA
14 Jun 2022

https://www.businesswire.com/news/home/20220331006007/en

BUSINESSWIRE
31 Mar 2022

https://www.businesswire.com/news/home/20220215005384/en

BUSINESSWIRE
15 Feb 2022
ValenzaBio, ProBioGen Enter Cell Line Pact
ValenzaBio, ProBioGen Enter Cell Line Pact

27 Jul 2021

// CONTRACT PHARMA

https://www.contractpharma.com/contents/view_breaking-news/2021-07-28/valenzabio-probiogen-enter-cell-line-pact/?widget=listSection

CONTRACT PHARMA
27 Jul 2021

https://www.lonza.com/news/2021-06-18-15-00

PRESS RELEASE
18 Jun 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty